1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatitis C Pricing and Reimbursement

Hepatitis C Pricing and Reimbursement

  • January 2015
  • -
  • Datamonitor Healthcare
  • -
  • 74 pages

The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni’s clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the large budgetary impact of treating all eligible patients, which will exert a significant strain on healthcare systems.

This report addresses the following questions:
- What reimbursement restrictions have been imposed by US payers and how do they differ between major brands?
- Which payers have imposed patient prioritization and how do the strategies differ between countries?
- How are European payers controlling expenditure on hepatitis C drugs?
- In which markets did Sovaldi have the best outcome of the health technology assessment?

Table Of Contents

Hepatitis C Pricing and Reimbursement
EXECUTIVE SUMMARY
MARKET CONTEXT
1. The hepatitis C market is undergoing a seismic shift, 2. Budgetary impact of hepatitis C therapies is causing payer pushback, 3. Marketed hepatitis C products in the US, Japan, and five major EU markets, 4. Pipeline hepatitis C treatments in late-stage development, 5. Price assumptions, 6. Bibliography

US
7. Pricing, 8. Reimbursement, 9. Bibliography

JAPAN
10. Price premiums are awarded for added benefit or innovation, 11. Pricing of launched hepatitis C treatments, 12. Treatment guidelines have been changed in the light of recent approvals, 13. Bibliography

FIVE MAJOR EU MARKETS
14. Pricing, 15. Reimbursement and health technology assessment, 16. Bibliography

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Therapy Market

1 day ago

Related Market Segments :

Therapy
Hepatitis C

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.